Halozyme to Present at Investor Conference and Scientific Meeting

SAN DIEGO--(BUSINESS WIRE)--Mar. 11, 2009-- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets, today announced that David A. Ramsay, Halozyme's CFO, will present at the Cowen and Company 29^th Annual Healthcare Conference on Wednesday, March 18, 2009 at 8:00 a.m. EDT (5:00 a.m. PDT) at the Marriott Copley Place in Boston.

Interested parties can access a live audio webcast and accompanying slides of the company presentation via the Internet by visiting the Investor Relations section of Halozyme's Web site at https://www.halozyme.com. An archived presentation will be available on the Halozyme Web site for 30 days following the presentation date.

Halozyme will also be presenting three posters with preclinical scientific data for PEGPH20 at the American Association of Cancer Research (AACR) Annual Meeting in Denver on April 19. Previous studies in mouse tumor models that produce hyaluronan have demonstrated that PEGPH20 removed HA from the tumor microenvironment and reduced tumor interstitial fluid pressure resulting in tumor growth inhibition and prolonged time to progression.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze Technology to Roche's biological therapeutics for up to 13 targets and with Baxter BioScience to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID. Halozyme's research pipeline candidates target significant areas of unmet medical need. For more information visit https://www.halozyme.com.

Source: Halozyme Therapeutics, Inc.

HalozymeRobert H. UhlSenior Director, Investor [email protected]